Osaka University

Ono Pharmaceutical Co., Ltd.

Terumo Kabushiki Kaisha

Nipro Corporation

Rohto Pharmaceutical Co., Ltd.

Satsuki Fukushima

Yoshiki Sawa

Shigeru Miyagawa

Yoshiki Sakai

Atsuhiro Saito

Takayuki Maruyama

Kazuhisa Matsuda

Shigeo Masuda

Hiroko Iseoka

Yoshiki Watanabe

Toru Kuratani

Koichi Toda

Daisuke Kajita

Takayoshi Ueno

Nagako Sougawa

It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.

Transplant material for treatment of heart disease

A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.

Myocardial cell sheet

The present invention provides a drug-eluting stent graft for preventing stent graft-related complications as well as treating aneurysm. Specifically, the present invention relates to a drug-eluting stent graft comprising a drug, a drug-retaining agent and a stent graft, and a method for therapy of aneurysm including the use of the drug-eluting stent graft.

Drug-eluting stent graft

Provided is an advanced heart failure treatment material, as a myocardial/cardiovascular regeneration device, that self-assembles, which can improve the universality and be used in an emergency by commercialization with no need of cell-culturing (cell-free) by controlling stem cells, and has a high therapeutic effect on the fundamental treatment of intractable cardiovascular diseases, in particular, advanced heart failure, in which not only the saving of lives but also improving the patient's quality of life (QOL) are urgent issues. The advanced heart failure treatment material includes a pharmaceutical agent, an agent holding for the pharmaceutical agent, and a myocardial support device.

Advanced heart failure treatment material as myocardial/cardiovascular regeneration device

Growing community of inventors

Suita, Japan

Satsuki Fukushima